Creative Planning Adaptimmune Therapeutics PLC Transaction History

Creative Planning

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 03, 2022	BUY	$1.06 - $2.41 $13,650 - $31,035	12,878 New	12,878 $14,000
Q3 2019 Nov 01, 2019	SELL	$1.43 - $3.81 $145,428 - $387,469	-101,698 Closed	0 $0
Q1 2019 Apr 24, 2019	SELL	$3.63 - $6.06 $72,600 - $121,199	-20,000 Reduced 16.43%	101,698 $437,000
Q4 2018 Feb 01, 2019	BUY	$3.76 - $14.16 $3,000 - $11,299	798 Added 0.66%	121,698 $700,000
Q3 2018 Oct 25, 2018	BUY	$8.27 - $13.56 $148,860 - $244,080	18,000 Added 17.49%	120,900 $1.64 Million
Q2 2018 Jul 20, 2018	BUY	$10.42 - $13.74 $41,680 - $54,960	4,000 Added 4.04%	102,900 $1.22 Million
Q1 2018 Apr 18, 2018	BUY	$7.1 - $11.56 $228,754 - $372,451	32,219 Added 48.32%	98,900 $1.11 Million
Q4 2017 Jan 17, 2018	BUY	$6.68 - $8.74 $178,229 - $233,191	26,681 Added 66.7%	66,681 $445,000
Q3 2017 Oct 17, 2017	BUY	$4.93 - $8.93 $197,200 - $357,200	40,000	40,000 $328,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.